fluorouracil has been researched along with Breast Cancer, Male in 43 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 9.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 9.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 9.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| " Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) were eligible for the study." | 9.09 | A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 9.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 9.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities." | 7.91 | Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019) |
| " The present study, therefore, aimed at measuring interstitial tumor 5-fluorouracil (5-FU) pharmacokinetics and 5-FU transfer rates from plasma into the tumor interstitium in breast cancer patients." | 7.69 | 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. ( Blochl-Daum, B; Eichler, HG; Gnant, M; Helbich, T; Jakesz, R; Jansen, B; Mader, RM; Müller, M; Steger, GG; Steiner, B, 1997) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 5.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 5.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "This phase II study in breast cancer patients assessed the utility of a single 6 mg subcutaneous dose of pegfilgrastim administered on day 9 of an intravenous (IV) "split" CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2) and 5-fluorouracil 600 mg/m(2)) chemotherapy regimen administered on days 1 and 8 and repeated every 28 days for 6 cycles." | 5.14 | Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. ( Bacon, P; Casas, A; Castellanos, J; Duque, A; Falcone, A; Gridelli, C; Lawrinson, S; Mansutti, M; Mattioli, R; Skacel, T, 2009) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 5.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| " Patients with breast cancer scheduled to receive FAC chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) were eligible for the study." | 5.09 | A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 5.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "Thirty-two patients undergoing adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or doxorubicin-CMF for stages I to II breast cancer were included after having chemotherapy delays due to neutropenia (absolute neutrophil count [ANC] < 1." | 5.08 | Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. ( Albanell, J; Baselga, J; Bellmunt, J; Bermejo, B; Carulla, J; Eres, N; Gallardo, E; Ribas, A; Solé-Calvo, LA; Vera, R; Vidal, R, 1996) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 5.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities." | 3.91 | Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019) |
| " Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted." | 3.91 | [A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome]. ( Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K, 2019) |
| "The subjects of this study were 45 patients with locally advanced breast cancer (LABC), who received the cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) regimen as NACT." | 3.77 | Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. ( Agrawal, D; Bajpai, P; Chandra, R; Mehrotra, PK; Mishra, A, 2011) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| " The present study, therefore, aimed at measuring interstitial tumor 5-fluorouracil (5-FU) pharmacokinetics and 5-FU transfer rates from plasma into the tumor interstitium in breast cancer patients." | 3.69 | 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. ( Blochl-Daum, B; Eichler, HG; Gnant, M; Helbich, T; Jakesz, R; Jansen, B; Mader, RM; Müller, M; Steger, GG; Steiner, B, 1997) |
| "Patients with early breast cancer surgically treated and eligible to adjuvant chemotherapy were enrolled." | 2.76 | Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. ( Albrile, F; Biggi, A; Bobbio, M; Feola, M; Francini, A; Garrone, O; Merlano, M; Occelli, M; Visconti, G, 2011) |
| "Patients with inflammatory breast cancer or more than nine ipsilateral lymph node involvement without evidence of distant metastasis were randomized to receive either standard dose 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) every 3 weeks for nine courses (control) or six courses of FAC followed by two courses of cyclophosphamide (5." | 2.69 | A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma. ( Aref, IM; Cross, PW; Gertler, SZ; Grimard, LJ; Hanson, J; Huan, SD; Malik, ST; St Cyr, DA; Stewart, DJ; Tomiak, EM; Verma, S; Yau, JC, 2000) |
| " Forty-five patients were evaluable for response (nine per dosing group)." | 2.68 | Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. ( Affronti, ML; Cartee, L; Gilbert, C; Hoke, JA; Hussein, AM; Moore, S; Petros, WP; Rosner, GL; Ross, M; Rubin, P, 1995) |
| "Male breast cancer is a rare disease and the incidence has increased over the past 25 years." | 2.44 | [Clinical research advancement on male breast cancer]. ( Guo, XT; Liu, WC; Xue, Y, 2007) |
| "The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown." | 1.39 | Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013) |
| "Identifying breast cancer patients at high risk of developing cardiotoxicity after anthracycline therapy would be of value in guiding the use of these agents." | 1.39 | Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. ( Feola, M; Garrone, O; Lo Nigro, C; Merlano, M; Monteverde, M; Vivenza, D, 2013) |
| "Thromboembolism is a well recognised complication of systemic chemotherapy and cancer." | 1.37 | The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. ( Boleti, K; Darby, A; Nolan, L; Simmonds, P, 2011) |
| "Between 1974 and 1988, 31 male breast cancer patients were prospectively enrolled on study MB-82 in the National Cancer Institute." | 1.34 | A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. ( Anderson, WF; Berman, AW; Lippman, ME; Steinberg, SM; Swain, SM; Vatas, U; Walshe, JM, 2007) |
| "Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes." | 1.34 | Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007) |
| " In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events." | 1.33 | [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006) |
| "According to our data, breast cancer most frequently occurred in patients of 45-49 years old." | 1.33 | [Clinical analysis of resectable breast cancer: a report of 6 263 cases]. ( Fu, JH; Huang, ZF; Lin, P; Long, H; Rong, TH; Tang, J; Wang, SY; Wang, X; Yang, MT; Zeng, CG, 2005) |
| "Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma." | 1.33 | Inflammatory breast cancer in a male. ( Choueiri, MB; El Saghir, NS; El-Hajj, II; Otrock, ZK; Tawil, AN, 2005) |
| "The prevalence of male breast cancer increases with age, and the presentation occurs at an average age of approximately 60 years, 10 years older than in females with the disease." | 1.32 | [Male breast cancer]. ( Kuroi, K; Toi, M, 2003) |
| "A total of 6 breast cancer patients, 5 with local recurrent tumors on their anterior chest wall and 1 with far advanced primary breast tumor, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432." | 1.31 | [Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer]. ( Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 18 (41.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stavraka, C | 1 |
| Pouptsis, A | 1 |
| Okonta, L | 1 |
| DeSouza, K | 1 |
| Charlton, P | 1 |
| Kapiris, M | 1 |
| Marinaki, A | 1 |
| Karapanagiotou, E | 1 |
| Papadatos-Pastos, D | 1 |
| Mansi, J | 1 |
| Tashima, Y | 1 |
| Kusanagi, K | 1 |
| Takeda, Y | 1 |
| Yoshimatsu, K | 1 |
| Ishida, T | 1 |
| Shinohara, S | 1 |
| Hirai, A | 1 |
| Imanishi, N | 1 |
| Ichiki, Y | 1 |
| Tanaka, F | 1 |
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Del Medico, P | 1 |
| Laudadio, L | 1 |
| Tomao, S | 1 |
| Giannarelli, D | 1 |
| Pizzuti, L | 1 |
| Sergi, D | 1 |
| Barba, M | 1 |
| Maugeri-Saccà, M | 1 |
| Vivenza, D | 1 |
| Feola, M | 2 |
| Garrone, O | 2 |
| Monteverde, M | 1 |
| Merlano, M | 2 |
| Lo Nigro, C | 1 |
| Kaczmarek, K | 1 |
| Wiącek, MP | 1 |
| Sulewski, A | 1 |
| Kubaszewski, Ł | 1 |
| Kaczmarczyk, J | 1 |
| Nowakowski, A | 1 |
| Wei, L | 1 |
| Liang, X | 1 |
| Li, S | 1 |
| Liu, J | 1 |
| Cihan, YB | 1 |
| Saura, C | 1 |
| Garcia-Saenz, JA | 1 |
| Xu, B | 1 |
| Harb, W | 1 |
| Moroose, R | 1 |
| Pluard, T | 1 |
| Cortés, J | 1 |
| Kiger, C | 1 |
| Germa, C | 1 |
| Wang, K | 1 |
| Martin, M | 2 |
| Baselga, J | 2 |
| Kim, SB | 1 |
| Occelli, M | 1 |
| Francini, A | 1 |
| Biggi, A | 1 |
| Visconti, G | 1 |
| Albrile, F | 1 |
| Bobbio, M | 1 |
| Mattioli, R | 1 |
| Gridelli, C | 1 |
| Castellanos, J | 1 |
| Duque, A | 1 |
| Falcone, A | 1 |
| Mansutti, M | 1 |
| Bacon, P | 1 |
| Lawrinson, S | 1 |
| Skacel, T | 1 |
| Casas, A | 1 |
| Njiaju, UO | 1 |
| Truica, CI | 1 |
| Arowolo, OA | 1 |
| Akinkuolie, AA | 1 |
| Lawal, OO | 1 |
| Alatise, OI | 1 |
| Salako, AA | 1 |
| Adisa, AO | 1 |
| Buccimazza, I | 1 |
| Kaufmann, M | 1 |
| Maass, N | 1 |
| Costa, SD | 1 |
| Schneeweiss, A | 1 |
| Loibl, S | 1 |
| Sütterlin, MW | 1 |
| Schrader, I | 1 |
| Gerber, B | 1 |
| Bauer, W | 1 |
| Wiest, W | 1 |
| Tomé, O | 1 |
| Distelrath, A | 1 |
| Hagen, V | 1 |
| Kleine-Tebbe, A | 1 |
| Ruckhaeberle, E | 1 |
| Mehta, K | 1 |
| von Minckwitz, G | 1 |
| Nolan, L | 1 |
| Darby, A | 1 |
| Boleti, K | 1 |
| Simmonds, P | 1 |
| Mishra, A | 1 |
| Chandra, R | 1 |
| Mehrotra, PK | 1 |
| Bajpai, P | 1 |
| Agrawal, D | 1 |
| Gonzalez-Perez, LM | 1 |
| Infante-Cossio, P | 1 |
| Crespo-Torres, S | 1 |
| Sanchez-Gallego, F | 1 |
| Makhson, A | 1 |
| Gligorov, J | 1 |
| Lichinitser, M | 1 |
| Lluch, A | 1 |
| Semiglazov, V | 1 |
| Scotto, N | 2 |
| Mitchell, L | 1 |
| Tjulandin, S | 1 |
| Blum, JL | 1 |
| Barrios, CH | 1 |
| Feldman, N | 1 |
| Verma, S | 2 |
| McKenna, EF | 1 |
| Lee, LF | 1 |
| Gralow, J | 1 |
| Kuroi, K | 1 |
| Toi, M | 1 |
| Yang, MT | 1 |
| Rong, TH | 1 |
| Huang, ZF | 1 |
| Zeng, CG | 1 |
| Long, H | 1 |
| Fu, JH | 1 |
| Lin, P | 1 |
| Wang, X | 2 |
| Wang, SY | 1 |
| Tang, J | 1 |
| Choueiri, MB | 1 |
| Otrock, ZK | 1 |
| Tawil, AN | 1 |
| El-Hajj, II | 1 |
| El Saghir, NS | 1 |
| Ohta, K | 1 |
| Dohden, K | 1 |
| Morishita, M | 1 |
| Hayashi, H | 1 |
| Hattori, M | 1 |
| Hosokawa, O | 1 |
| Morita, M | 1 |
| Kaizaki, Y | 1 |
| Kiya, T | 1 |
| Walshe, JM | 1 |
| Berman, AW | 1 |
| Vatas, U | 1 |
| Steinberg, SM | 1 |
| Anderson, WF | 1 |
| Lippman, ME | 1 |
| Swain, SM | 1 |
| Karakuzu, A | 1 |
| Koc, M | 1 |
| Ozdemir, S | 1 |
| Fontana, S | 1 |
| Ghilardi, R | 1 |
| Barbaglio, A | 1 |
| Amaddeo, P | 1 |
| Faldi, F | 1 |
| Pericotti, S | 1 |
| Zabel-du Bois, A | 1 |
| Milker-Zabel, S | 1 |
| Wannenmacher, M | 1 |
| Debus, J | 1 |
| Eucker, J | 1 |
| Kühnl, A | 1 |
| Possinger, K | 1 |
| Xue, Y | 1 |
| Guo, XT | 1 |
| Liu, WC | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Cartee, L | 1 |
| Petros, WP | 1 |
| Rosner, GL | 1 |
| Gilbert, C | 1 |
| Moore, S | 1 |
| Affronti, ML | 1 |
| Hoke, JA | 1 |
| Hussein, AM | 1 |
| Ross, M | 1 |
| Rubin, P | 1 |
| Tanaka, Y | 1 |
| Ohmori, Y | 1 |
| Toki, T | 1 |
| Okazaki, Y | 1 |
| Ogoshi, S | 1 |
| Ogawa, Y | 1 |
| Ribas, A | 1 |
| Albanell, J | 1 |
| Bellmunt, J | 1 |
| Solé-Calvo, LA | 1 |
| Bermejo, B | 1 |
| Gallardo, E | 1 |
| Vidal, R | 1 |
| Vera, R | 1 |
| Eres, N | 1 |
| Carulla, J | 1 |
| Müller, M | 1 |
| Mader, RM | 1 |
| Steiner, B | 1 |
| Steger, GG | 1 |
| Jansen, B | 1 |
| Gnant, M | 1 |
| Helbich, T | 1 |
| Jakesz, R | 1 |
| Eichler, HG | 1 |
| Blochl-Daum, B | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Tuğ, T | 1 |
| Karaayvaz, M | 1 |
| Akgül, H | 1 |
| Bascioni, R | 1 |
| Giorgi, F | 1 |
| Silva, RR | 1 |
| Acito, L | 1 |
| Giustini, L | 1 |
| De Signoribus, G | 1 |
| Giuliodori, L | 1 |
| Testa, E | 1 |
| Cantore, M | 1 |
| Fiorentini, G | 1 |
| Cavazzini, G | 1 |
| Molani, L | 1 |
| Morandi, C | 1 |
| Caforio, M | 1 |
| Caleffi, G | 1 |
| Mambrini, A | 1 |
| Zamagni, D | 1 |
| Smerieri, F | 1 |
| Hidalgo, M | 1 |
| Rinaldi, D | 1 |
| Medina, G | 1 |
| Griffin, T | 1 |
| Turner, J | 1 |
| Von Hoff, DD | 1 |
| Taguchi, T | 1 |
| Tsukamoto, F | 1 |
| Watanabe, T | 1 |
| Yoneda, K | 1 |
| Takamura, Y | 1 |
| Hojo, S | 1 |
| Shiba, E | 1 |
| Noguchi, S | 1 |
| Davidson, NG | 1 |
| Davis, AS | 1 |
| Woods, J | 1 |
| Snooks, S | 1 |
| Cheverton, PD | 1 |
| Yau, JC | 1 |
| Gertler, SZ | 1 |
| Hanson, J | 1 |
| Grimard, LJ | 1 |
| Malik, ST | 1 |
| Aref, IM | 1 |
| Cross, PW | 1 |
| Tomiak, EM | 1 |
| Stewart, DJ | 1 |
| St Cyr, DA | 1 |
| Huan, SD | 1 |
| Takei, H | 1 |
| Iino, Y | 1 |
| Horiguchi, J | 1 |
| Maemura, M | 1 |
| Koibuchi, Y | 1 |
| Yokoe, T | 1 |
| Morishita, Y | 1 |
| Jordan, VC | 1 |
| Sugiyama, Y | 1 |
| Saji, S | 1 |
| Miya, K | 1 |
| Kunieda, K | 1 |
| Takao, H | 1 |
| Kawaguchi, Y | 1 |
| Kimura, A | 1 |
| Honda, S | 1 |
| Matsui, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer[NCT00124111] | Phase 2 | 0 participants | Interventional | Completed | |||
| A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer[NCT00811135] | Phase 2 | 88 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 71.4 |
| Lapatinib Naive Subjects P1 | 72.1 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 73.0 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.
| Intervention | weeks (Median) |
|---|---|
| Prior Lapatinib Subjects | 48.3 |
| Lapatinib Naive Subjects P1 | 46.3 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 46.3 |
MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg/m^2 (Number) |
|---|---|
| Capecitabine in Combination With Neratinib | 1500 |
MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg (Number) |
|---|---|
| Neratinib in Combination With Capecitabine | 240 |
Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| N160 + C1500 | 0 |
| N160 + C2000 | 2 |
| N200 + C2000 | 2 |
| N240 + C1500 | 0 |
| N240 + C2000 | 2 |
| N + C MTD - No Prior Lap | 0 |
| N + C MTD - Prior Lap | 0 |
Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 57.1 |
| Lapatinib Naive Subjects P1 | 63.9 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 63.5 |
DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 12.7 |
Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 70 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 40 |
Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 66 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 62 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 31.8 |
Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 75.0 |
PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.2 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.5 |
2 reviews available for fluorouracil and Breast Cancer, Male
| Article | Year |
|---|---|
Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2012 |
[Clinical research advancement on male breast cancer].
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis | 2007 |
12 trials available for fluorouracil and Breast Cancer, Male
| Article | Year |
|---|---|
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2011 |
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 2009 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2010 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Dos | 1995 |
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1996 |
Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
Topics: Administration, Topical; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1999 |
FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brea | 1999 |
A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Car | 2000 |
29 other studies available for fluorouracil and Breast Cancer, Male
| Article | Year |
|---|---|
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2019 |
[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cilostazol; Combined M | 2019 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh | 2013 |
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma.
Topics: Adult; Aged; Angiotensinogen; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Failure and success in the treatment of breast carcinoma in men: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Breast Neoplasms, Male; Carcinoma, Ductal | 2014 |
[Adenoid cystic carcinoma of the breast:report of 25 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma | 2010 |
The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Br | 2010 |
Invited commentary: The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a nigerian semiurban teaching hospital: a single-center descriptive study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Br | 2010 |
The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2011 |
Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 2011 |
Mandibular metastases as first clinical sign of an occult male breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Bre | 2012 |
[Male breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Combined Modality Ther | 2003 |
[Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Inflammatory breast cancer in a male.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cyclophospha | 2005 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas | 2006 |
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, A | 2007 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; C | 2006 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast | 2007 |
[Postoperative radiotherapy of the chest wall in patients with male breast cancer].
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Ch | 2007 |
[Systemic therapy of male breast cancer].
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antine | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcin | 1995 |
5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients.
Topics: Adipose Tissue; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neop | 1997 |
Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1997 |
Four years experience of primary intra-arterial chemotherapy (PIAC) for locally advanced and recurrent breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast | 1997 |
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Car | 2001 |
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisp | 2001 |